Annual Meeting Highlights

ASH 2020 Meeting Highlights in Myelodysplastic Syndromes
ASH 2020 Meeting Highlights in Myelodysplastic Syndromes
CME, CPE, CNE
Mikkael A. Sekeres, MD, MS; Guillermo Garcia-Manero, MD; Rami S. Komrokji, MD
Release Date: April 15, 2021
Expiration Date: April 15, 2022

In this activity, experts will discuss exciting abstracts from the 2020 ASH Annual Meeting related to myelodysplastic syndromes (MDS). Topics will include genomic and somatic mutations of MDS, personalized decision tools for MDS diagnosis, data on lenalidomide for non-transfusion-dependent, lower-risk del(5q) MDS, biomarkers that correlate with luspatercept response, the effect of luspatercept on MDS with ring sideroblasts, phase 2 trial result of imetelstat in lower-risk MDS, and therapeutic doublets such as azacitidine plus venetoclax and azacitidine plus pevonedistat in higher-risk MDS.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Bristol-Myers Squibb and Taiho Oncology, Inc.

CE ExpiredView Only, No Credit
 
ASH 2019 Annual Meeting Highlights in MDS
ASH 2019 Annual Meeting Highlights in MDS
CME, CPE, CNE
Jorge E. Cortes, MD; Guillermo Garcia-Manero, MD; Alan F. List, MD; Shyamala C. Navada, MD, MSCR; Eytan M. Stein, MD
Release Date: January 07, 2020
Expiration Date: January 07, 2021
In this activity, participants will hear key highlights taken from of a select group of abstracts which focused on some of the most impactful data in myelodysplastic syndromes (MDS), presented at the 2019 American Society of Hematology (ASH) 61st Annual Meeting. Leading experts in the field of MDS will share their insights on a variety of abstracts, covering topics including, but not limited to: venetoclax therapy in MDS, magrolimab with azacitidine, rigosertib with azacitidine, and enasidenib in patients with high-risk IDH2-mutated MDS.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Astex Pharmaceuticals, Celgene Corporation, and Takeda Oncology.
CE ExpiredView Only, No Credit
 
Highlights from the 15th International Symposium on MDS
Highlights from the 15th International Symposium on MDS
CME, CPE, CNE
Guillermo Garcia-Manero, MD; Jean-Pierre Issa, MD; Casey O'Connell, MD, FACP; David P. Steensma, MD, FACP
Release Date: September 04, 2019
Expiration Date: September 04, 2020
Four thought leaders in MDS cover select presentations from the 15th International Symposium on MDS. They will share insights on the current standard of care, selecting appropriate strategies for each individual patient, and where checkpoint inhibitors fit into practice. Additionally, participants will hear the status of clinical trials combining hypomethylating agents with immune checkpoint inhibitors in MDS.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Astex Pharmaceuticals, Celgene Corporation, and Takeda Oncology.
CE ExpiredView Only, No Credit